What is a Cosmetic Product Safety Report (CPSR)?
A cosmetic product needs to be safe for human health when used under normal and reasonably foreseeable conditions of use. All cosmetic products placed on the EU market must be subject to a safety assessment conducted by a qualified person. A Cosmetic Product Safety Report (CPSR) shall be done and included in the Product Information File (PIF).
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

EU LEGAL FRAMEWORK ON COSMETIC PRODUCTS

The Regulation (EC) No 1223/2009 establishes the rules that all cosmetic products made available on the European Union (EU) market must comply with, in order to ensure the functioning of the internal market and a high level of protection of human health.

Only cosmetic products for which a legal or natural person is designated as a “Responsible Person” (RP) can be placed on the EU market. The RP is fully responsible for safety and legal compliance. (see previous post)

According to Article 3 of this Regulation, “a cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use“. In order to demonstrate that a cosmetic product complies with Article 3, the RP must guarantee that the product has undergone a safety assessment and that a Cosmetic Product Safety Report (CPSR) is set up.

The CPSR must be carried out by a qualified safety assessor, with a university diploma (or other evidence of formal qualification) in pharmacy, toxicology, medicine or similar (recognized as equivalent by a Member State).

COSMETIC PRODUCT SAFETY REPORT (CPSR)

The CPSR consists of two parts (Part A and Part B) that should contain, as minimum, the following information:

  • PART A – Cosmetic product safety information
    • Quantitative and qualitative composition of the cosmetic product
    • Physical/chemical characteristics and stability of the cosmetic product
    • Microbiological quality
    • Impurities, traces, information about the packaging material
    • Normal and reasonably foreseeable use
    • Exposure to the cosmetic product
    • Exposure to the substances
    • Toxicological profile of the substances
    • Undesirable effects and serious undesirable effects
    • Information on the cosmetic product

  • PART B – Cosmetic product safety assessment
    • Assessment conclusion
    • Labelled warnings and instructions of use
    • Reasoning
    • Assessor’s credentials and approval of part B

The CPSR must be kept up to date, taking into acount relevant information generated after the product is placed on the market (e.g., amendments to Regulation).

The Cosmetic Product Safety Report is part of the Product Information File (PIF), which should be kept for a period of 10 years, counting on the date on which the last batch of the product was placed on the market.

In sum, the CPSR is a mandatory document for all cosmetic products in the EU, as it demonstrates the safety and efficacy of a cosmetic product.

Critical Catalyst has a team of qualified EU safety assessors with vast experience in conducting CPSRs. For more information, please feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »